Merck Stock Overvalued After Cancer Vaccine Breakthrough? MRK Outlook 2026

Merck & Co. (NYSE: MRK) jumped more than 12% after announcing positive Phase 3 results for its personalized mRNA cancer vaccine collaboration with Moderna, pushing the stock near record highs around $152 per share.

The market reaction reflects more than a successful clinical trial. Investors are reassessing whether the combination of Moderna’s mRNA technology and Merck’s Keytruda franchise could create a new long-term growth engine and reduce concerns surrounding Keytruda’s future patent expiration.

However, after the sharp rally, a key question has emerged: Is Merck stock still undervalued based on future growth potential, or has the market already priced in too much optimism?

Why Did Merck Stock Rally After the Cancer Vaccine Breakthrough?

The main catalyst behind MRK’s recent move was the success of the INTerpath-001 Phase 3 clinical trial conducted by Merck and Moderna.

The trial evaluated: mRNA-4157 (V940) personalized cancer vaccine + Keytruda

for high-risk melanoma patients after surgical removal.

According to Merck’s official announcement, the combination therapy achieved statistically significant improvements in:

Longer-term follow-up data showed:

• 49% reduction in risk of recurrence or death
• 59% reduction in risk of distant metastasis or death

The results strengthened the market view that personalized cancer vaccines could become an important next-generation cancer treatment platform.

Can Cancer Vaccine Growth Extend Merck’s Keytruda Franchise?

The biggest investment debate around Merck is not only about the vaccine itself, but whether it can extend the commercial life of Keytruda.

Keytruda remains Merck’s largest revenue driver. According to Merck’s financial reports:

• Keytruda generated approximately $8.37 billion in quarterly revenue;
• It represents a significant portion of Merck’s pharmaceutical sales.

However, investors have been concerned about the long-term impact of Keytruda’s patent expiration timeline.

The cancer vaccine breakthrough changes this discussion.

Instead of replacing Keytruda, the combination therapy could potentially strengthen its position by creating a new treatment approach where patients receive both immunotherapy and personalized vaccination.

This could help Merck expand into additional cancer indications, including:

• melanoma;
• lung cancer;
• kidney cancer;
• pancreatic cancer.

The market is therefore pricing in the possibility that Keytruda’s revenue cycle could be extended beyond current expectations.

Is Merck Stock Overvalued After the Rally?

After the recent move, valuation has become the main discussion among investors.

As of August 2026:

Merck’s valuation depends heavily on whether future pipeline growth can offset potential pressure from Keytruda’s patent cycle.

Bullish valuation argument

Supporters believe the market is still underestimating:

• personalized cancer vaccine potential;
• expansion into additional cancer types;
• Merck’s global oncology sales network.

If the therapy receives regulatory approval and achieves strong commercial adoption, analysts may increase long-term earnings expectations.

Bearish valuation argument

More cautious investors argue that:

• the stock already reflects significant future success;
• regulatory approval is not guaranteed;
• manufacturing personalized mRNA vaccines at scale remains challenging.

Therefore, the current valuation debate is less about the clinical result itself and more about whether future earnings growth can justify the higher market expectations.

Merck Stock Price Outlook 2026: Possible Scenarios

Future MRK performance will likely depend on regulatory progress, commercial adoption, and broader pharmaceutical market conditions.

These scenarios are market-based estimates for evaluating possible outcomes and do not represent guaranteed future prices.

Merck vs Moderna: Who Benefits More From the Cancer Vaccine Opportunity?

The breakthrough also changed expectations for Moderna.

For Moderna, the data provided important validation that mRNA technology can expand beyond COVID-19 vaccines into oncology.

For Merck, the advantage comes from its existing commercial infrastructure.

From a business perspective, Merck may have a clearer path to monetizing the technology because it already has a large oncology customer base.

Risks That Could Challenge Merck’s Growth Story

Despite the positive clinical results, several risks remain.

First, successful Phase 3 data does not immediately translate into revenue. Regulatory approval, pricing negotiations, and manufacturing capacity will determine the commercial outcome.

Second, personalized cancer vaccines require patient-specific sequencing and production processes. Scaling this model across millions of patients could present operational challenges.

Finally, valuation risk remains important. If future revenue growth does not match current market expectations, the stock could face a valuation adjustment even with strong scientific progress.

How WEEX Provides Access to Global Stock Token Opportunities

For investors following global healthcare and technology trends, tokenized stocks provide another way to track traditional market assets through Web3 platforms.

WEEX currently supports hundreds of stock-related token assets across sectors, including healthcare and technology markets. Users can explore available assets through WEEX Stock Token Market and WEEX TradFi Market.

WEEX also provides a Proof of Reserves mechanism based on a 1:1 reserve structure to enhance transparency and asset security. More details are available through WEEX Proof of Reserves.

Conclusion: Is Merck Stock Overvalued or Entering a New Growth Cycle?

Merck’s cancer vaccine breakthrough has shifted the market conversation from short-term earnings toward long-term oncology growth potential.

The key question for investors is no longer whether the technology is promising, but whether Merck can successfully convert this scientific breakthrough into sustainable revenue growth.

The company’s future valuation will likely depend on three factors:

• regulatory approval progress;
• Keytruda franchise expansion;
• commercial success of personalized cancer vaccines.

For now, Merck represents a classic market debate between a premium valuation supported by innovation and the risk of expectations becoming too optimistic too quickly.